Effectiveness and mechanisms of adipose-derived stem cell therapy in animal models of Parkinson's disease: a systematic review and meta-analysis.

Adipose-derived stem cells Animal model Meta-analysis Neurogenesis Neuroprotection Parkinson’s disease Stem cell therapy

Journal

Translational neurodegeneration
ISSN: 2047-9158
Titre abrégé: Transl Neurodegener
Pays: England
ID NLM: 101591861

Informations de publication

Date de publication:
29 04 2021
Historique:
received: 15 01 2021
accepted: 13 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 21 12 2021
Statut: epublish

Résumé

Animal models provide an opportunity to assess the optimal treatment way and the underlying mechanisms of direct clinical application of adipose-derived stem cells (ADSCs). Previous studies have evaluated the effects of primitive and induced ADSCs in animal models of Parkinson's disease (PD). Here, eight databases were systematically searched for studies on the effects and in vivo changes caused by ADSC intervention. Quality assessment was conducted using a 10-item risk of bias tool. For the subsequent meta-analysis, study characteristics were extracted and effect sizes were computed. Ten out of 2324 published articles (n = 169 animals) were selected for further meta-analysis. After ADSC therapy, the rotation behavior (10 experiments, n = 156 animals) and rotarod performance (3 experiments, n = 54 animals) were improved (P < 0.000 01 and P = 0.000 3, respectively). The rotation behavior test reflected functional recovery, which may be due to the neurogenesis from neuronally differentiated ADSCs, resulting in a higher pooled effect size of standard mean difference (SMD) (- 2.59; 95% CI, - 3.57 to - 1.61) when compared to that of primitive cells (- 2.18; 95% CI, - 3.29 to - 1.07). Stratified analyses by different time intervals indicated that ADSC intervention exhibited a long-term effect. Following the transplantation of ADSCs, tyrosine hydroxylase-positive neurons recovered in the lesion area with pooled SMD of 13.36 [6.85, 19.86]. Transplantation of ADSCs is a therapeutic option that shows long-lasting effects in animal models of PD. The potential mechanisms of ADSCs involve neurogenesis and neuroprotective effects. The standardized induction of neural form of transplanted ADSCs can lead to a future application in clinical practice.

Identifiants

pubmed: 33926570
doi: 10.1186/s40035-021-00238-1
pii: 10.1186/s40035-021-00238-1
pmc: PMC8081767
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

14

Subventions

Organisme : the Research Fund for Doctor Innovation of Peking Union Medical Colleg
ID : 2019-1001-14
Organisme : Natural Science Foundation of Beijing Municipality (CN)
ID : 5171001
Organisme : CAMS Innovation Fund for Medical Sciences
ID : 2019-I2M-1-006

Références

Stem Cell Reports. 2018 Jul 10;11(1):171-182
pubmed: 29910127
Cytotherapy. 2015 Feb;17(2):199-214
pubmed: 25457280
J Neuroinflammation. 2018 Nov 30;15(1):333
pubmed: 30501635
Lancet Neurol. 2020 May;19(5):452-461
pubmed: 32171387
Nature. 2017 Aug 30;548(7669):592-596
pubmed: 28858313
Stem Cells. 2007 Apr;25(4):818-27
pubmed: 17420225
Mol Biol Rep. 2019 Oct;46(5):5257-5272
pubmed: 31327120
Lancet Neurol. 2017 Nov;16(11):877-897
pubmed: 28931491
Aesthet Surg J. 2016 Feb;36(2):229-36
pubmed: 26238455
Cytotherapy. 2013 Apr;15(4):467-80
pubmed: 23403361
Stem Cell Res Ther. 2016 Jun 13;7(1):84
pubmed: 27296220
J Cell Physiol. 2019 Aug;234(8):13762-13772
pubmed: 30637730
Cell Reprogram. 2015 Jun;17(3):221-6
pubmed: 26053521
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
ASN Neuro. 2018 Jan-Dec;10:1759091418777438
pubmed: 29809058
Surg Today. 2016 Jul;46(7):835-42
pubmed: 26342817
Exp Neurol. 2013 Sep;247:25-38
pubmed: 23542820
Stem Cell Res Ther. 2020 Jun 3;11(1):212
pubmed: 32493480
PLoS One. 2013;8(4):e59438
pubmed: 23565152
PLoS One. 2012;7(9):e45757
pubmed: 23049854
Nat Rev Neurol. 2015 Sep;11(9):492-503
pubmed: 26240036
Neural Regen Res. 2014 Apr 15;9(8):798-805
pubmed: 25206892
Tissue Eng. 2001 Apr;7(2):211-28
pubmed: 11304456
Nat Rev Neurosci. 2017 Sep;18(9):515-529
pubmed: 28747776
Brain. 1999 Aug;122 ( Pt 8):1437-48
pubmed: 10430830
Cell Transplant. 2018 Mar;27(3):456-470
pubmed: 29756519
Curr Stem Cell Res Ther. 2017;12(4):326-347
pubmed: 27842480
Prog Neurobiol. 2017 Sep;156:69-89
pubmed: 28457671
J Neurosci Res. 2019 Sep;97(9):1095-1109
pubmed: 31119788
Stem Cell Rev Rep. 2015 Feb;11(1):133-49
pubmed: 25120226
Mol Biol Rep. 2019 Dec;46(6):5841-5858
pubmed: 31396803
Chem Soc Rev. 2017 Oct 16;46(20):6255-6275
pubmed: 28816316
Lancet Neurol. 2006 Jan;5(1):75-86
pubmed: 16361025
World J Stem Cells. 2017 Aug 26;9(8):107-117
pubmed: 28928907
Cell. 2015 Oct 8;163(2):324-39
pubmed: 26451483
Am J Sports Med. 2019 Jun;47(7):1722-1733
pubmed: 31100005
Cell Cycle. 2017 May 3;16(9):841-851
pubmed: 28296571
Aging Dis. 2020 May 9;11(3):465-469
pubmed: 32489692
N Engl J Med. 2020 May 14;382(20):1926-1932
pubmed: 32402162
Regen Med. 2015 May;10(4):431-46
pubmed: 26022763
Neurobiol Aging. 2015 Oct;36(10):2885-92
pubmed: 26242706
Hum Cell. 2017 Apr;30(2):60-71
pubmed: 28210976
Exp Neurol. 2008 Mar;210(1):14-29
pubmed: 18061169
Cell Signal. 2019 Oct;62:109350
pubmed: 31254605
Lancet. 2016 Jan 16;387(10015):217
pubmed: 26842286
BMC Med Res Methodol. 2014 Mar 26;14:43
pubmed: 24667063
Int J Nanomedicine. 2020 Feb 26;15:1297-1308
pubmed: 32161459
Neurotherapeutics. 2019 Apr;16(2):404-415
pubmed: 30361931
Stem Cells Int. 2017;2017:9142493
pubmed: 29445405
Neuron. 2003 Sep 11;39(6):889-909
pubmed: 12971891
Nat Rev Neurol. 2016 Feb;12(2):65-6
pubmed: 26782330
Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2049-2066
pubmed: 31340667

Auteurs

Keya Li (K)

NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, 100021, China.

Xinyue Li (X)

NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, 100021, China.

Guiying Shi (G)

NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, 100021, China.

Xuepei Lei (X)

NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, 100021, China.

Yiying Huang (Y)

NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, 100021, China.

Lin Bai (L)

NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, 100021, China. bailin49@163.com.

Chuan Qin (C)

NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, 100021, China. qinchuan@pumc.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH